For how we live.
STAREE randomised 9,971 Australians aged 70 and over to atorvastatin or placebo. Cardiovascular events fell by 30%. Death, dementia and persistent disability, taken together, did not move.
After 12 months, HbA1c was 6.5% among people managed by community health workers versus 7.1% among those referred to clinics. With 103 participants analysed, the confidence interval crosses zero.
In a single-centre trial of 100 patients with decompensated cirrhosis, six months of atorvastatin cut recurrent complications from 72% to 36% — a striking but preliminary result needing larger confirmation.
An individual-participant meta-analysis of 123,940 people in 19 double-blind trials tested 66 label-listed harms. Four survived correction — none of them the ones patients hear about most.